Recently, the Food and Drug Administration (FDA) issued a black box warning to consumers and healthcare providers warning of the risk of tardive dyskinesia with the long-term or high-dose use of metoclopramide, more commonly known as Reglan, a medication prescribed for the treatment of disorders like heartburn caused by gastroesophageal reflux disease. Tardive dyskinesia is a condition in which a person develops involuntary movements of their muscles. Elderly patients, especially women, are at an increased risk of developing the condition while using Reglan.

Recorded: June 3, 2009

Courtesy of: Beasley Allen Video

Keywords: Pharmaceutical, Reglan